Keeping Generics Off the Market

Syngenta, Corteva “Loyalty Programs” Restrain Competition Class Action

Syngenta Crop Protection AG, Syngenta Corporation, Syngenta Crop Protection, LLC, and Corteva, Inc. are “basic” manufacturers of pesticides, meaning they invent, develop, and patent pesticides. When the patents expire, other manufacturers can make generic versions. But the complaint for this class action alleges that the companies use anticompetitive “loyalty programs” to curtail the amount of  Read more

Syngenta, Corteva Monopoly of Pesticides with Certain Active Ingredients Class Action

This antitrust class action takes aim at certain large, basic makers of pesticides—Syngenta Crop Protection, AG, Syngenta Corporation, Syngenta Crop Protection, LLC, and Corteva, Inc. The complaint alleges they stifled competition by creating loyalty programs that keep distributors from selling lower-priced generic products that contain the same active ingredients and that could save farmers money.  Read more

Namenda Antitrust Indirect Payors Settlement

The defendants in this Brand Settlement of an antitrust lawsuit include Actavis, plc, Forest Laboratories, LLC, (makers of Namenda), Merz GmbH, Merz Pharmaceuticals GmbH, and Merz Pharma GmbH & Co. KgaA (the patent holders for Namenda). The complaint alleged that these Brand Defendants, along with the Generic Defendants, conspired in a monopolization scheme to keep  Read more

Opana ER Delayed Generics Antitrust Settlement

Impax Laboratories, Inc. is settling its part of an antitrust class action about an alleged conspiracy between itself and a group of Endo companies, including Endo Health Solutions, Inc., Endo Pharmaceuticals, Inc., and Penwest Pharmaceuticals Co. The complaint alleged that, in June 2010, Impax and Endo entered into a “pay for delay” agreement delaying the  Read more

Syngenta, Corteva “Loyalty Programs” Restrict Competition Class Action

This antitrust class action bring suit against Syngenta Crop Protection AG, Syngenta Corporation, Syngenta Crop Protection, LLC, and Corteva, Inc., alleging that they have instituted “loyalty programs” for distributors of their pesticides containing certain ingredients. The complaint alleges that the real purpose and effect of these loyalty programs is to restrict the sale of competing  Read more

Remicade Antitrust Settlement

Johnson & Johnson and Janssen Biotech, Inc. are putting up $25 million to settle an antitrust class action centering on anticompetitive actions they allegedly took to protect their drug Remicade (infliximab) from competition. The complaint alleged the companies violated federal and state antitrust laws and consumer protection laws by attempting to keep new entrants out  Read more

Syngenta, Corteva Anticompetitive “Loyalty Programs” Class Action

The pesticide industry is similar to the pharmaceutical industry in a number of ways, says the complaint for this class action: Both rely on patent protections, both have safety requirements, and in both, generics enter the market after patents have expired. But the complaint brings suit against pesticide companies Syngenta Crop Protection AG, Syngenta Corporation,  Read more

Bristol-Myers Squibb HIV cART Drugs Antitrust Direct Purchaser Partial Settlement

This is a partial settlement of an antitrust class action against Bristol-Myers Squibb Company, ER Squibb & Sons, LLC, and others. The complaints alleged that the companies violated antitrust laws by conspiring to extend patent protection for antiretroviral drugs for treating human immunodeficiency virus (HIV cART drugs) by engaging in anticompetitive conduct and restraining competition,  Read more

Ranbaxy TPP Generic Nexium, Diovan, and Valcyte Settlement

Sun Pharmaceutical Industries, Ltd. and Ranbaxy, Inc. are settling combined class actions alleging generic drug manufacturer Ranbaxy made misrepresentations about both the conditions in its plants and the results of analyses on the integrity of data at the plants. This allowed it to obtain “tentative approval” from the Food and Drug Administration (FDA) and a  Read more

Glumetza Antitrust Settlement

This settlement resolves an antitrust class action against a number of companies or groups of companies, including Bausch Health Companies, Inc., Salix Pharmaceuticals, Ltd., Depomed, Inc., and Assertio Therapeutics, Inc. The complaint alleged that the companies conspired to delay and impede the entry to the market of less expensive, generic versions of Glumetza, with Lupin  Read more